

INCIDENCE OF HEPATITIS C VIRUS (HCV) IN A MULTICENTER COHORT OF HIV- POSITIVE PATIENTS IN SPAIN 2004–2011: INCREASING RATES OF HCV DIAGNOSIS BUT NOT OF HCV SEROCONVERSION

**Sobrino-Vegas P.¹, Monge S.¹, Serrano S.², Gutiérrez F.³, Blanco J.R.⁴, Santos I.⁵,
del Romero J.⁶, Segura F.⁷, Portilla J.⁸, del Amo J.¹, Moreno S.² and CoRIS⁹**

(1) Red de Investigación en Sida, Instituto de Salud Carlos III, Madrid (2) H.U. Ramón y Cajal, Madrid (3) H. General U. de Elche (4) H. San Pedro, La Rioja (5) H.U. de La Princesa, Madrid (6) C.S. Sandoval, Madrid (7) H.U. Parc Taulí, Sabadell (8) H.General de Alicante (9) Cohorte de la Red de Investigación en Sida, Spain

Objectives

We aim to describe rates and risk factors of Hepatitis C virus (HCV) diagnoses, follow-up HCV testing and HCV seroconversion from 2004 - 2011 in a cohort of HIV-positive persons in Spain.




Methods

- CERES is a multicentre, open and prospective cohort recruiting adult HIV positive patients naïve to antiretroviral therapy in 13 of the 17 regions of Spain from 2004 onwards.
 - ☒ We analysed patients with at least one negative and one follow-up HCV serology.
 - ☒ The date of HCV diagnosis was the date the first HCV test was positive. The date of HCV seroconversion was estimated using two different methods: a) the midpoint between the last negative and the first positive HCV test for any time window, b) a multiple imputation technique, assuming that seroconversion was equally probable at any given moment during that time window.
 - ☒ Patients were considered at risk from the date of cohort entry to the date of their last HCV negative serology or the date of HCV diagnosis/seroconversion.
 - ☒ Incidence rates (IR) were calculated and a multivariate poisson regression was used to estimate adjusted Relative Rates (aIRR).

Subjects 53

Time trends of rates of HCV diagnoses, HCV infections, Rates and associated risk factors

All Subjects



# Sero-	Person-				
---------	---------	--	--	--	--

	converters	years	IR	IRR (CI 95%)	aIRR (CI 95%)
SEX					
Male	33	4,694.28	0.70	1	1
Female	13	941.43	1.38	1.96 (1.03-3.76)	1.58 (0.78-3.20)
TRANSMISSION CATEGORY					
Heterosexuals	19	1,846.42	1.03	1	1
Injecting drug users	5	53.31	9.38	9.11 (2.86-29.08)	9.63 (2.88-32.19)
Homo/bisexual men	21	3,592.28	0.58	0.57 (0.24-1.36)	0.81 (0.29-2.27)
Other /Unknown/ Not available	1	143.70	0.70	0.68 (0.10-4.79)	0.77 (0.11-5.50)
AGE AT ENTRY					
< =30 years	11	1,866.73	0.59	1	1
31-40 years	19	2,350.63	0.81	1.37 (0.57-3.30)	1.38 (0.57-3.30)
41-50 years	12	960.44	1.25	2.12 (1.15-3.90)	1.66 (0.85-3.24)
> 50 years	4	457.91	0.87	1.48 (0.68-3.24)	1.29 (0.53-3.14)
CD4+ T-Cell Count					
<200 cells/mm ³	8	455.76	1.76	2.36 (1.17-4.75)	1.93 (0.90-4.15)
=> 200 cells/mm ³	38	5,100.96	0.74	1	1
Not available	0	79.00	0.00		
TOTAL	46	5,635.72	0.82		
	CoRIS - HOMOSEXUAL/BISEXUAL MEN (MSM)				
	# Sero-converters	Person-years	IR	IRR (CI 95%)	aIRR (CI 95%)
AGE AT ENTRY					

AGE AT ENTRY						
<=30 years	5	1,314.77	0.38	1		1
31-40 years	9	1,562.66	0.58	1.51 (0.44-5.22)	1.51 (0.44-5.22)	
41-50 years	6	490.79	1.22	3.21 (1.66-6.23)	3.21 (1.66-6.23)	
> 50 years	1	224.06	0.45	1.17 (0.24-5.67)	1.17 (0.24-5.67)	
TOTAL	21	3,592.28	0.58			
	CoRIS – HETEROSEXUALS (HTX)					
	# Sero-converters	Person-years	IR	IRR (CI 95%)	aiRR (CI 95%)	
SEX						

For MSM, subjects aged 40-50 compared to 30 or less .
Among HTX, female sex and having <200 CD4-count .

The report increases limits on new treatments but not to rises in HCV

- ☒ Risk of HCV seroconversion was higher for injecting drug users compared to heterosexuals.
 - ☒ In men who have sex with men, HCV IR increases with age.
 - ☒ Among heterosexuals, HCV IR is higher in women and in subjects impaired immunological situation.